3'SL (3´Sialyllactose Sodium Salt) is an abundant sialylated HMO in human milk. Some primary known benefits of 3'SL include reducing infection by inhibiting the adhesion of pathogenic bacteria and their toxins. Also, 3'SL can positively support brain development by affecting cognition and regulating neurons.
Regulatory filings for 3'SL have been made in EU and US and preparation is on way for other major markets.
GlyCare™ 3SL will be commercially available from 2020.
HMO help support immunity. Clinical studies have reported a relationship between HMO and immune outcomes in infants. HMO are reported to support an infant’s immune system. HMO may help reduce the risk of infection. HMO may help reduce the risk of certain infections in infants.
Emerging science from preclinical studies suggest that 3’SL may have a potential role in brain development. Preclinical studies in rodent and pigs reported that supplementation with HMO’s including 3’SL resulted in an enriched sialic acid content in the brain. This may be important for infants serving as an important source of sialic acid for brain development (5,6).
Clinical data suggest HMOs support intestinal health in infants. Preclinical and clinical data indicate that HMOs support the growth of beneficial bacteria/bifidobacteria. HMOs may help support the growth of beneficial bacteria/bifidobacteria which are believed to be important for immune and intestinal development and health.
Emerging data from pre-clinical models and breast milk studies suggest that HMOs may play a role reducing the incidence of certain allergic manifestations.